Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies has announced the initiation of a second Phase I single center trial of AZD2820, an obesity compound selected by AstraZeneca from research collaboration.
Subscribe to our email newsletter
The single-blind, randomized trial is expected to enrol 72 obese patients, with a body mass index between 30 and 35kg/m².
The primary objective of the placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820.
AZD2820 is a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity.
Palatin president and chief executive officer Carl Spana said, "We are delighted that AstraZeneca is progressing the clinical development of AZD2820, a compound synthesized in our laboratories during the research collaboration."